Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Source: Pixabay

Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients

Thanks to a Phase 2 trial, pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Ph+ ALL, now have a new treatment option. The FDA has announced approval of Sprycel…

Continue Reading Sprycel Approved by FDA for Pediatric Ph+ Acute Lymphoblastic Leukemia Patients
Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
frolicsomepl / Pixabay

Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy

According to a story from Market Screener, an analysis of real-world data (data gathered outside of the clinical setting) suggests that the drug eltrombopag, marketed as Revolade, offers substantial advantages…

Continue Reading Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy

Experimental Treatment For Small Cell Lung Cancer Receives Orphan Drug Designation

According to a story from pm360online.com, the drug development company Cytori Therapeutics recently announced that its investigational product ATI-1123 has been granted Orphan Drug designation from the US Food and…

Continue Reading Experimental Treatment For Small Cell Lung Cancer Receives Orphan Drug Designation
A Supplemental New Drug Application Has Been Submitted for a Potential Treatment of Immune Thrombocytopenia
jarmoluk / Pixabay

A Supplemental New Drug Application Has Been Submitted for a Potential Treatment of Immune Thrombocytopenia

Dova Pharmaceutics has submitted a supplemental New Drug Application to the US FDA on behalf of Doptelet® (avatrombopag), which is being researched as an investigational treatment of immune thrombocytopenia in…

Continue Reading A Supplemental New Drug Application Has Been Submitted for a Potential Treatment of Immune Thrombocytopenia
New Drug Approved in the EU for Treating Hereditary Transthyretin Amyloidosis
Source: Pixabay.com

New Drug Approved in the EU for Treating Hereditary Transthyretin Amyloidosis

According to a story from bioportfolio.com, two companies, Ionis Pharmaceuticals, Inc., and its affiliate Akcea Pharmaceuticals, recently announced that its product inotersen (to be marketed as TEGSEDI) has gained approval…

Continue Reading New Drug Approved in the EU for Treating Hereditary Transthyretin Amyloidosis
Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety
Source: Pixabay

Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety

Caplacizumab is a medicine that has been developed to treat acquired thrombotic thrombocytopenic purpura (TTP). TTP causes serious symptoms. such as thrombocytopenia, a condition in which a patient doesn't have enough platelets. A…

Continue Reading Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety
What You Need to Know About Low Thrombocytes
{By Prof. Erhabor Osaro (Own work) [CC BY-SA 4.0 (http://creativecommons.org/licenses/by-sa/4.0)], via Wikimedia Commons]

What You Need to Know About Low Thrombocytes

Thrombocytopenia. The condition doesn’t sound so bad. Low Platelets. It seems as though you have a low savings. You can’t buy that Snickers bar, you have low platelets. You can’t…

Continue Reading What You Need to Know About Low Thrombocytes
Lasers are the Exciting, Safe New Way to Treat Thrombocytopenia
Source: pixabay.com

Lasers are the Exciting, Safe New Way to Treat Thrombocytopenia

If you're living with thrombocytopenia (that is, a severely low level of platelets in your blood), then Dr. Mei X. Wu may be your new best friend. The associate professor…

Continue Reading Lasers are the Exciting, Safe New Way to Treat Thrombocytopenia